Autolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026GlobeNewsWire • Tuesday
Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business UpdatesGlobeNewsWire • Tuesday
Autolus Therapeutics to Participate in the Jefferies Global Healthcare ConferenceGlobeNewsWire • Monday
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026GlobeNewsWire • 11/04/26
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 11/03/26
Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026GlobeNewsWire • 10/26/26
All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to BuyZacks Investment Research • 10/05/26
Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026GlobeNewsWire • 10/05/26
Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus NephritisGlobeNewsWire • 09/09/26
Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026GlobeNewsWire • 08/03/26
Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive AdvisorsGlobeNewsWire • 08/03/26
Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 06/10/26
Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy?Zacks Investment Research • 06/01/26
Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026GlobeNewsWire • 05/21/26